Search Results
Jun 21, 2025, 21:35 ET Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions
Association's (ADA) 85th Scientific Sessions. Details are listed below： Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract Number：1886-LBPresentation Form: PosterPresentation
More news about: Innovent Biologics
Jun 18, 2025, 09:00 ET AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
MariTide MariTide is a bispecific glucagon-like peptide 1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist being investigated for the treatment of obesity and Type 2 diabetes mellitus. As a pioneering peptide-antibody conjugate molecule with a
More news about: Amgen
Jun 12, 2025, 21:00 ET Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
Innovent Biologics Title: A novel antibody-peptide conjugate targeting PCSK9, GLP-1R, GCGR, GIPR improves cardiovascular risk markers in preclinical studyAbstract #：1886-LBPresentation Form: Poster
More news about: Innovent Biologics
Jun 12, 2025, 10:45 ET Deep Apple Therapeutics kündigt Zusammenarbeit mit Novo Nordisk zur Entdeckung und Entwicklung oraler Therapeutika für kardiometabolische Erkrankungen an
umfangreiche Pipeline von GPCR-Zielprogrammen aufgebaut, darunter einen MRGPRX2-Antagonisten, der sich in der IND-Zulassungsphase befindet, und einen GIPR-Antagonisten, der kurz vor der IND-Zulassungsphase steht. Weitere Informationen finden Sie unter
More news about: Deep Apple
Jun 11, 2025, 16:10 ET Deep Apple Therapeutics anuncia colaboración con Novo Nordisk en enfermedades cardiometabólicas
Deep Apple ha desarrollado una amplia cartera de programas de dianas para GPCR, incluyendo un antagonista de MRGPRX2 en desarrollo y un antagonista de GIPR próximo a iniciarse en estudios que permitan la IND. Para más información, visite
More news about: Deep Apple
Jun 11, 2025, 07:00 ET Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases
targets in inflammatory and metabolic diseases. Deep Apple has built a rich pipeline of GPCR target programs, including a MRGPRX2 antagonist in, and a GIPR antagonist nearing, IND-enabling studies. For more information, visit
More news about: Deep Apple
Jun 11, 2025, 07:00 ET Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases
targets in inflammatory and metabolic diseases. Deep Apple has built a rich pipeline of GPCR target programs, including a MRGPRX2 antagonist in, and a GIPR antagonist nearing, IND-enabling studies. For more information, visit
More news about: Deep Apple